Financial news, mergers and acquisitions, partnerships, and alliances.
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
The partnership will allow Serosep's customers to benefit from standardized diagnostic interpretation supported by artificial intelligence and automation.
The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.
The test cartridge runs on the company's Unyvero platform and covers 103 diagnostic targets for various pathogens and markers of antibiotic resistance.
The firm aims to offer a clinical service next year for predicting immunotherapy response and adverse immune reactions.